
## Tycho Bismeijer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/724660/publications.pdf Version: 2024-02-01



TYCHO RISMELLED

#	Article	IF	CITATIONS
1	Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Scientific Reports, 2016, 6, 18517.	3.3	143
2	The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting. Breast Cancer Research, 2017, 19, 99.	5.0	58
3	BRCA1â€like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. Molecular Oncology, 2015, 9, 1528-1538.	4.6	54
4	A multilevel pan-cancer map links gene mutations to cancer hallmarks. Chinese Journal of Cancer, 2015, 34, 439-49.	4.9	38
5	Radiogenomic Analysis of Breast Cancer by Linking MRI Phenotypes with Tumor Gene Expression. Radiology, 2020, 296, 277-287.	7.3	37
6	Complementary Value of Contralateral Parenchymal Enhancement on DCE-MRI to Prognostic Models and Molecular Assays in High-risk ER+/HER2â~ Breast Cancer. Clinical Cancer Research, 2017, 23, 6505-6515.	7.0	18
7	Molecular characterization of breast and lung tumors by integration of multiple data types with functional sparse-factor analysis. PLoS Computational Biology, 2018, 14, e1006520.	3.2	13
8	Genomic data integration by WON-PARAFAC identifies interpretable factors for predicting drug-sensitivity in vivo. Nature Communications, 2019, 10, 5034.	12.8	12
9	Breast adipocyte size associates with ipsilateral invasive breast cancer risk after ductal carcinoma in situ. Npj Breast Cancer, 2021, 7, 31.	5.2	11
10	Are contralateral parenchymal enhancement on dynamic contrast-enhanced MRI and genomic ER-pathway activity in ER-positive/HER2-negative breast cancer related?. European Journal of Radiology, 2019, 121, 108705.	2.6	9
11	Comprehensive multiplexed immune profiling of the ductal carcinoma in situ immune microenvironment regarding subsequent ipsilateral invasive breast cancer risk. British Journal of Cancer, 0, , .	6.4	5
12	Contralateral parenchymal enhancement on MRI is associated with tumor proteasome pathway gene expression and overall survival of early ER+/HER2-breast cancer patients. Breast, 2021, 60, 230-237.	2.2	0